Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Retained Earnings: 2019-2024

Historic Retained Earnings for 4D Molecular Therapeutics (FDMT) over the last 6 years, with Dec 2024 value amounting to -$576.2 million.

  • 4D Molecular Therapeutics' Retained Earnings fell 39.73% to -$735.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$735.7 million, marking a year-over-year decrease of 39.73%. This contributed to the annual value of -$576.2 million for FY2024, which is 38.73% down from last year.
  • Latest data reveals that 4D Molecular Therapeutics reported Retained Earnings of -$576.2 million as of FY2024, which was down 38.73% from -$415.3 million recorded in FY2023.
  • Over the past 5 years, 4D Molecular Therapeutics' Retained Earnings peaked at -$135.7 million during FY2020, and registered a low of -$576.2 million during FY2024.
  • Its 3-year average for Retained Earnings is -$435.3 million, with a median of -$415.3 million in 2023.
  • Data for 4D Molecular Therapeutics' Retained Earnings shows a maximum YoY plummeted of 71.69% (in 2020) over the last 5 years.
  • Over the past 5 years, 4D Molecular Therapeutics' Retained Earnings (Yearly) stood at -$135.7 million in 2020, then tumbled by 52.56% to -$207.0 million in 2021, then tumbled by 51.93% to -$314.5 million in 2022, then tumbled by 32.06% to -$415.3 million in 2023, then plummeted by 38.73% to -$576.2 million in 2024.